Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year

According to data from Data Treasure, as of now, 19 listed companies have released their semi-annual reports for 2025. In terms of net profit scale, DRTG, JI LIN AO DONG, BUCHANG PHARMA, ZuoLi Pharmaceutical, and Qizheng Tibetan Medicine are at the forefront, with net profits of 1.92 billion yuan, 1.263 billion yuan, 598 million yuan, 378 million yuan, and 358 million yuan, respectively. Among them, DRTG, JI LIN AO DONG, and BUCHANG PHARMA have all achieved year-on-year growth in net profit of more than double. DRTG expects to achieve a net profit attributable to the parent company of 1.84 billion to 2 billion yuan in the first half of 2025, a year-on-year increase of 180% to 204%. The main reason for the performance growth is the sale of 12% equity in the joint venture company Tianjin Shike, with disposal gains of 1.54 billion yuan and a net profit after tax of 1.31 billion yuan. Great Wall Securities pointed out that DRTG has successfully developed the "Jing Wan Hong Skin Factor," transforming traditional Chinese medicine wisdom into safe and effective skincare ingredients. The formulation of Jing Wan Hong ointment has shown positive potential in the field of skin care, and with the company's in-depth development in the future, it is expected to further open up the market for traditional Chinese medicine skin health. In addition, TMSP has successfully turned losses into profits. During the reporting period, the company continuously strengthened its layout and terminal sales in the pharmaceutical, health products, and medical device sectors, driving a significant year-on-year increase in product sales and sales revenue, thereby enhancing the overall profitability of the company. The stock hit the daily limit today, with well-known speculative funds appearing on the leaderboard, net buying 9.5309 million yuan